SR

Active Director Director DIN 07635320
DIN 07635320 First appointment Dec 2016 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2016
Shareholding value •••• Premium profile

About Suman Rai

Data last updated:

Suman Rai is a Director at Angloswift Drugs India Private Limited (since 2016). The company operates in Chemicals. Angloswift Drugs India Private Limited reported revenue of ₹5.1 Lakh (FY 2025).

DIN 07635320
Primary Designation Director
Industry Chemicals
First Appointment 28 Dec 2016
Oldest Company Age 9 yrs
Largest company Angloswift Drugs India Private Limited · ₹5.1 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director28 Dec 20162016₹5.1 Lakh (FY 2025)Active

Board colleagues of Suman Rai

NameDINCompanyDesignation
Braj Bhushan Rai07647633Angloswift Drugs India Private LimitedDirector

Directorship timeline

Open interactive timeline →
Angloswift Drugs India Private Limited
Premium access

Shareholding and investment profile for Suman Rai

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Suman Rai

Suman Rai currently holds 1 directorship: Angloswift Drugs India Private Limited (Director, since 28 Dec 2016, revenue ₹5.1 Lakh (FY 2025)).

Suman Rai was first appointed on 28 Dec 2016 as Director at Angloswift Drugs India Private Limited.

The current boards of Suman Rai's companies include Braj Bhushan Rai (Angloswift Drugs India Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available